You are here: Industry Insights > Market News

News List

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC PR Newswire
March 05, 2025
Antengene announced XPOVIO® (selinexor) was approved for commercialization in Indonesia. It's the first XPO1 inhibitor there. Since 2024, it has been approved in multiple APAC markets for various cancer indications.
HighTide Therapeutics Announces Publication of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus Open ACN Newswire
March 05, 2025
HighTide Therapeutics announced that Phase 2 data of berberine ursodeoxycholate for treating T2DM was published in JAMA Network Open.
The Chinese Carbon Ion Center Heyou Hospital Selects RayStation PR Newswire
March 04, 2025
RaySearch Laboratories AB announced Heyou Hospital in China ordered RayStation for RMB 51 million. It's a major order, boosts RaySearch's lead in particle treatment planning.
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin") PRNewswire
March 04, 2025
Raziel Therapeutics initiates phase 3 study in China for RZL-012 to reduce submental fat, partnering with JuveStar, product expected in 2027.
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 in Melanoma PR Newswire
March 03, 2025
Innovent announced that the first patient has been dosed in its registrational study evaluating IBI363 as Keytruda® in patients with unresectable loc.
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept PR Newswire
March 03, 2025
Callio Therapeutics announced its launch with the closing of a $187.0 million Series A financing round.
Wren Laboratories Announces Discontinuation of NETest 1.0 in Favor of Advanced NETest 2.0 Biotech Newswire
March 03, 2025
Wren Laboratories discontinues NETest 1.0, replacing it with NETest 2.0. An AI-enhanced liquid biopsy, it offers high accuracy and sets a new non-invasive monitoring standard.
Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum PharmaSources
February 26, 2025
InnoCare Pharma Announced today that the Phase II Results of Orelabrutinib for the Treatment of Relapsing-Remitting Multiple scler.
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S. PR Newswire
February 25, 2025
Another Step Forward in Global Expansion
China's First Domestic CTLA-4 Inhibitor, in Combination With Sintilimab as Neoadjuvant Treatment for Colon Cancer PR Newswire
February 24, 2025
NMPA Accepts NDA and Grants Priority Review Designation to combine with Sintilimab as Treatment for Colon Cancer.